Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 3, 2005, Pages 203-211

  Smee, Donald F ^a   Wandersee, Miles K ^a   Bailey, Kevin W ^a   Hostetler, Karl Y ^b   Holy, Antonin ^c   Sidwell, Robert W ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Cidofovir; HDP cidofovir; Orthopoxvirus; Resistance; Ribavirin; S2242; Vidarabine

Indexed keywords

2 AMINO 7 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]PURINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)GUANINE; CIDOFOVIR; CYCLOPHOSPHAMIDE; HOE 961; NUCLEOSIDE DERIVATIVE; RIBAVIRIN; UNCLASSIFIED DRUG; VIDARABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG SCREENING; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MOUSE; NONHUMAN; PLAQUE FORMING CELL; POXVIRUS INFECTION; PRIORITY JOURNAL; QUANTUM YIELD; RESPIRATORY TRACT INFECTION; SCID MOUSE; VACCINIA VIRUS; VERO CELL; VIROGENESIS; VIRULENCE; VIRUS ATTENUATION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS TITRATION; WILD TYPE;

EID: 27244451444     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600306     Document Type: Article

References (28)

1. Andrei G, Snoeck R, De Clercq E, Esnouf R, Fiten P & Opdenakker G (2000) Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. Journal of General Virology 81:639-648.
2. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E & Huggins JW (2000) Cidofovir (HPMPC) protects mice against lethal aerosol or intranasal cowpox virus challenge. Journal of Infectious Diseases 181:10-19.
3. Cianci C, Genovesi EV, Lamb L, Medina I, Yang Z, Zadjura L, Yang H, D'Arienzo C, Sin N, Yu KL, Combrink K, Li Z, Colonno R, Meanwell N, Clark J & Krystal M (2004) Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrobial Agents & Chemotherapy 48:2448-2454.
4. Coen DM, Furman PA, Gelep PT & Schaffer PA (1982) Mutations in the herpes simplex virus DNA polymerase gene can confer resistance to 9-β-D-arabinofuranosyladenine. Journal of Virology 41:909-918.
5. De Clercq E, Luczak M, Shugar D, Torrence PF, Waters JW & Witkop B (1976) Effect of cytosine arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proceedings of the Society for Experimental Biology & Medicine 151:487-490.
6. De Clercq E, Holy A & Rosenberg I (1989) Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrobial Agents & Chemotherapy 33:185-191.
7. Enserink M (2003) Infectious diseases. SARS researchers report new animal models. Science 302:213.
8. Goswami BB, Borek E, Sharma OK, Fujitaki J & Smith RA (1979) The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochemical & Biophysical Research Communications 89:830-836.
9. Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC & Hitchcock MJ (1992) Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]cytosine. Molecular Pharmacology 41:197-202.
10. Keith KA, Wan WB, Ciesla SL, Beadle JR, Hostetler KY & Kern ER (2004) Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrobial Agents & Chemotherapy 48:1869-1871.
11. Neyts J & De Clercq E (1993) Efficacy of (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. Journal of Medical Virology 41:242-246.
12. Neyts J & De Clercq E (2001) Efficacy of 2-amino-7-[(1,3-dihydroxy-2- propoxy)methyl]purine treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrobial Agents & Chemotherapy 45:84-87.
13. Neyts J, Andrei G, Snoeck R, Jahne G, Winkler I, Helsberg M, Balzarini J & De Clercq E (1994) The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication. Antimicrobial Agents & Chemotherapy 38:2710-2716.
14. Neyts J, Balzarini J, Andrei G, Chaoyong Z, Snoeck R, Zimmermann A, Mertens T, Karlsson A & De Clercq E (1998) Intracellular metabolism of the N7-substituted acyclic nucleoside analog 2-amino-7-(1,3-dihydroxy-2- propoxymethyl)purine, a potent inhibitor of herpesvirus replication. Molecular Pharmacology 53:157-165.
15. Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY & Kern ER (2004) Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrobial Agents & Chemotherapy 48:404-412.
16. Smee DF & Sidwell RW (2003) A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Research 57:41-52.
17. Smee DF & Sidwell RW (2004) Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2′-fluoro- arabinofuranosyl nucleosides. Nucleosides, Nucleotides & Nucleic Acids 23:375-383.
18. Smee DF, Bailey KW & Sidwell RW (2000) Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antiviral Chemistry & Chemotherapy 11:303-309.
19. Smee DF, Bailey KW & Sidwell RW (2001a) Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antiviral Chemistry & Chemotherapy 12:71-76.
20. Smee DF, Bailey KW, Wong M-H & Sidwell RW (2001b) Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Research 52:55-62.
21. Smee DF, Bray M & Huggins JW (2001c) Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antiviral Chemistry & Chemotherapy 12:327-335.
22. Smee DF, Bailey KW & Sidwell RW (2002a) Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy) methyl]purine and its orally active diacetate ester prodrug. Antiviral Research 54:113-120.
23. Smee DF, Sidwell RW, Kefauver D, Bray M & Huggins JW (2002b) Characterization of wild-type and cidofovir resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrobial Agents & Chemotherapy 46:1329-1335.
24. Smee DF, Bailey KW & Sidwell RW (2003) Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy 49:126-131.
25. Smee, DF, Wong M-H, Bailey KW, Beadle JR, Hostetler KY & Sidwell RW (2004) Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. International Journal of Antimicrobial Agents 23:430-437.
26. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK & Simon LN (1973) Mechanism of action of 1-β-D-ribofuranosyl-1,2,4- triazole-3-carboxamide (virazole), a new broad-spectrum antiviral agent. Proceedings of the National Academy of Sciences, USA 70:1174-1178.
27. Terry BJ, Mazina KE, Tuomari AV, Haffey ML, Hagen M, Feldman A, Slusarchyk WA, Young MG, Zahler R & Field AK (1988) Broad-spectrum antiviral activity of the acyclic guanosine phosphorate (R,S)-HPMPG. Antiviral Research 10:235-252.
28. Tignor GH, Kende M & Hanham CA (1992) Chemotherapeutic prevention of complications caused by vaccinia virus-vectored immunogen. Annals of the New York Academy of Sciences 653:334-343.